Literature DB >> 32067689

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.

M Mazzotta1, M Filetti1, A Rossi1, M Roberto1, M Occhipinti2, A Pernazza3, A Di Napoli4, S Scarpino4, A Vecchione4, R Giusti5, P Marchetti6.   

Abstract

Entities:  

Year:  2019        PMID： 32067689     DOI： 10.1016/j.annonc.2019.11.016

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report.

Authors:  Mingsheng Liu
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

Review 2.  Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.

Authors:  Paul Hofman
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.